AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,102,164 | -3.2% | 337,349 | -0.0% | 0.00% | 0.0% |
| Q2 2023 | $4,237,480 | +20.9% | 337,379 | +6.8% | 0.00% | 0.0% |
| Q1 2023 | $3,503,985 | -9.2% | 315,959 | +0.0% | 0.00% | 0.0% |
| Q4 2022 | $3,857,493 | +17.4% | 315,929 | +0.4% | 0.00% | 0.0% |
| Q3 2022 | $3,286,000 | -58.4% | 314,729 | -57.3% | 0.00% | -50.0% |
| Q2 2022 | $7,907,000 | +22.5% | 736,265 | +8.0% | 0.00% | +100.0% |
| Q1 2022 | $6,457,000 | -22.5% | 681,845 | -5.5% | 0.00% | -33.3% |
| Q4 2021 | $8,330,000 | +18.1% | 721,225 | -2.4% | 0.00% | 0.0% |
| Q3 2021 | $7,054,000 | +92.9% | 738,648 | +94.7% | 0.00% | +200.0% |
| Q2 2021 | $3,657,000 | -3.4% | 379,400 | -1.0% | 0.00% | -50.0% |
| Q1 2021 | $3,785,000 | -68.7% | 383,100 | -26.9% | 0.00% | -66.7% |
| Q4 2020 | $12,108,000 | +63.5% | 524,366 | 0.0% | 0.01% | +50.0% |
| Q3 2020 | $7,404,000 | -16.0% | 524,366 | -10.3% | 0.00% | -20.0% |
| Q2 2020 | $8,819,000 | +166.6% | 584,836 | +63.3% | 0.01% | +150.0% |
| Q1 2020 | $3,308,000 | -36.1% | 358,036 | -32.6% | 0.00% | -33.3% |
| Q4 2019 | $5,177,000 | +101.7% | 531,503 | +66.0% | 0.00% | +50.0% |
| Q3 2019 | $2,567,000 | -35.7% | 320,136 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $3,995,000 | +9.3% | 320,136 | +19.1% | 0.00% | 0.0% |
| Q1 2019 | $3,656,000 | -25.9% | 268,836 | -47.8% | 0.00% | -50.0% |
| Q4 2018 | $4,932,000 | +53.2% | 514,836 | +93.3% | 0.00% | +100.0% |
| Q3 2018 | $3,220,000 | -22.6% | 266,336 | 0.0% | 0.00% | -33.3% |
| Q2 2018 | $4,160,000 | +25.6% | 266,336 | +21.0% | 0.00% | +50.0% |
| Q1 2018 | $3,311,000 | -10.4% | 220,136 | -14.3% | 0.00% | -33.3% |
| Q4 2017 | $3,696,000 | -27.4% | 256,846 | -24.0% | 0.00% | -25.0% |
| Q3 2017 | $5,094,000 | +145.7% | 337,826 | +64.1% | 0.00% | +100.0% |
| Q2 2017 | $2,073,000 | +64.3% | 205,836 | +16.3% | 0.00% | +100.0% |
| Q1 2017 | $1,262,000 | -85.9% | 177,036 | -90.2% | 0.00% | -85.7% |
| Q4 2016 | $8,967,000 | -34.3% | 1,804,222 | -2.2% | 0.01% | -41.7% |
| Q3 2016 | $13,650,000 | +18.9% | 1,844,529 | -12.3% | 0.01% | +20.0% |
| Q2 2016 | $11,478,000 | -23.6% | 2,102,242 | +18.2% | 0.01% | -23.1% |
| Q1 2016 | $15,025,000 | -29.4% | 1,778,151 | -18.9% | 0.01% | -27.8% |
| Q4 2015 | $21,272,000 | -23.2% | 2,192,974 | +10.8% | 0.02% | -25.0% |
| Q3 2015 | $27,701,000 | +1140.5% | 1,980,077 | +1154.8% | 0.02% | +1100.0% |
| Q2 2015 | $2,233,000 | +5482.5% | 157,800 | +4164.9% | 0.00% | – |
| Q1 2015 | $40,000 | +29.0% | 3,700 | 0.0% | 0.00% | – |
| Q4 2014 | $31,000 | -81.0% | 3,700 | -95.3% | 0.00% | – |
| Q1 2014 | $163,000 | -15.5% | 78,565 | -4.5% | 0.00% | – |
| Q4 2013 | $193,000 | -13.1% | 82,265 | -14.0% | 0.00% | – |
| Q3 2013 | $222,000 | -1.8% | 95,665 | -1.6% | 0.00% | – |
| Q2 2013 | $226,000 | – | 97,191 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |